Abstract
SARS-CoV-2 continues to evolve, while the decline in clinical sequencing efforts hampers public health sectors to prepare for the menace of ongoing variant emergence and future COVID-19 surges.1 Wastewater-based epidemiology (WBE) has been proposed to provide complementary insights on the variants being transmitted in communities.2 However, limited research has been dedicated to the use sequencing methods for tracking disease prevalence and variant dynamics in wastewater, particularly on a large scale. Here, we employed a tiling amplicon sequencing to track the dynamics of variant of concern (VOC) in wastewater collected from Queensland, Australia from 2020 to 2022. RNA concentrations in wastewater measured by ATOPlex showed a stronger correlation and greater consistency with the number of daily new cases than a PCR-based method. The VOC dynamics observed in wastewater were largely in line with clinical reports. These findings support that WBE and sensitive sequencing methods can serve as a long-term approach for disease surveillance, thus aiding in disease outbreak prevention, control, and management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JG would like to acknowledge the Australian Research Council for funding support through Discovery Project (DP220101526). GN would like to acknowledge support from the Advance Queensland Industry Research Fellowship (RM2019002600) and an Early Career Postdoctoral Fellowship (ECPF23-8566329039) at the Faculty of Medicine, Nursing and Health Sciences of Monash University. We thank MGI Australia for sequencing support. The authors thank City of Gold Coast, Urban Utilities and Logan Water for their help in collecting samples. We thank Queensland Health for their help with data retrieval.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
